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ORIGINAL INVESTIGATION
Obesity and type 2 diabetes have 
additive effects on left ventricular remodelling 
in normotensive patients-a cross sectional study
Kirstie A. De Jong1* , Juliane K. Czeczor1,2,3, Smithamol Sithara1, Kevin McEwen1, Gary D. Loopaschuk4,5, 
Alan Appelbe6, Kimberly Cukier7, Mark Kotowicz8,9,10 and Sean L. McGee1
Abstract 
Background: It is unclear whether obesity and type 2 diabetes (T2D), either alone or in combination, induce left 
ventricular hypertrophy (LVH) independent of hypertension. In the current study, we provide clarity on this issue by 
rigorously analysing patient left ventricular (LV) structure via clinical indices and via LV geometric patterns (more 
commonly used in research settings). Importantly, our sample consisted of hypertensive patients that are routinely 
screened for LVH via echocardiography and normotensive patients that would normally be deemed low risk with no 
further action required.
Methods: This cross sectional study comprised a total of 353 Caucasian patients, grouped based on diagnosis of 
obesity, T2D and hypertension, with normotensive obese patients further separated based on metabolic health. 
Basic metabolic parameters were collected and LV structure and function were assessed via transthoracic echocar-
diography. Multivariable logistic and linear regression analyses were used to identify predictors of LVH and diastolic 
dysfunction.
Results: Metabolically healthy normotensive obese patients exhibited relatively low risk of LVH. However, normoten-
sive metabolically non-healthy obese, T2D and obese/T2D patients all presented with reduced normal LV geometry 
that coincided with increased LV concentric remodelling. Furthermore, normotensive patients presenting with both 
obesity and T2D had a higher incidence of concentric hypertrophy and grade 3 diastolic dysfunction than normoten-
sive patients with either condition alone, indicating an additive effect of obesity and T2D. Alarmingly these altera-
tions were at a comparable prevalence to that observed in hypertensive patients. Interestingly, assessment of LVPWd, 
a traditional index of LVH, underestimated the presence of LV concentric remodelling. The implications for which 
were demonstrated by concentric remodelling and concentric hypertrophy strongly associating with grade 1 and 3 
diastolic dysfunction respectively, independent of sex, age and BMI. Finally, pulse pressure was identified as a strong 
predictor of LV remodelling within normotensive patients.
Conclusions: These findings show that metabolically non-healthy obese, T2D and obese/T2D patients can develop 
LVH independent of hypertension. Furthermore, that LVPWd may underestimate LV remodelling in these patient 
groups and that pulse pressure can be used as convenient predictor of hypertrophy status.
Keywords: Obesity, Type 2 diabetes, Left ventricular hypertrophy, Left ventricular diastolic dysfunction, 
Echocardiography
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Background
Obesity and T2D are well-accepted risk factors for the 
development of left ventricular hypertrophy (LVH) [1, 
2]. However, it remains unclear as to whether these 
stresses are sufficient to cause LVH, independent of 
hypertension and other cardiac disease. This is largely 
due to the asymptomatic nature of LVH and the way in 
which risk is monitored in normotensive obese and/or 
T2D patients.
LVH is traditionally characterised by increased thick-
ness of the LV posterior wall diameter (LVPWd) and/
or increased LV mass [3]. There are three LV geomet-
ric patterns that can identify the type of LVH present, 
eccentric hypertrophy (increased LV mass), concentric 
remodelling [increased relative wall thickness (RWT) 
of the LVPWd, normal LV mass] and concentric hyper-
trophy (increased LV mass and increased RWT). These 
changes in cardiac structure are often accompanied 
by diastolic dysfunction (DD, impaired LV relaxation) 
and can be detected in obese patients via transtho-
racic echocardiography (TTE) [3]. However, requests 
for patients to undergo TTE are often restricted to 
those with chronic hypertension, or to those who have 
returned an abnormal electrocardiogram result after 
presenting with symptoms such as arrhythmia, short-
ness of breath or chest pain. Monitoring risk in obese 
and/or T2D patients this way presumes that without 
hypertension, obesity and T2D are insufficient stresses 
to induce LVH.
Major limitations of past studies are that obesity and 
T2D have often been considered one disease state, and 
the individual contributions of these diseases to LVH in 
the absence of hypertension have remained obscured. 
Furthermore, in studies that have appropriately distin-
guished obesity [4, 5] and T2D [6–8], there has been a 
propensity to use LV mass alone as an independent var-
iable to detect LVH, without assessing the RWT of the 
LV posterior wall. This restricts the type of LVH that 
can be detected to eccentric hypertrophy and prevents 
the detection of concentric remodelling and concentric 
hypertrophy. Previous studies suggest there is prognos-
tic value in assessment of LV geometric patterns, with 
increased LV mass and concentric hypertrophy in par-
ticular [9, 10] found to associate with increased risk of 
adverse cardiovascular events. Whether this prognostic 
value applies to normotensive patients with obesity and 
T2D remains unresolved.
The current study aimed to determine whether 
patients presenting with obesity and type 2 diabetes, 
either alone or in combination, exhibit LVH in the 
absence of hypertension. Both traditional indices of 
LVH and LV geometric patterns were used to identify 
LVH. Furthermore, we sought to determine whether LV 
geometry predicted the presence of diastolic dysfunc-
tion and whether routine metabolic parameters can be 
used to predict LVH in these patients.
Methods
Study approval
This cross sectional study comprised a total of 353 Cau-
casian patients, from the University Hospital Geelong 
and the Geelong Endocrinology and Diabetes Centre. 
The study was conducted in accordance with National 
Health and Medical Research Council (NHMRC) 
guidelines and was approved by the Human Research 
Ethics Committee (HREC) via the Barwon Health 
Research and Integrity Unit, in accordance to guide-
lines outlined in section 5 of the National Statement on 
Ethical Conduct in Human Research.
Participant groups
Based on the diagnosis of obesity, T2D and hyperten-
sion, patients were designated into one of the following 
groups; normotensive obese (N.Obese) n = 58, normo-
tensive T2D (N.T2D) n = 41, normotensive obese/T2D 
(N.Obese/T2D) n =  42, hypertensive obese (H.Obese) 
n = 71, hypertensive T2D (H.T2D) n = 74 and hyper-
tensive obese/T2D (H.Obese/T2D) n  =  67. For the 
diagnosis of obesity, T2D and hypertension, basic clini-
cal and metabolic data were collected for each par-
ticipant consisting of age, sex, height, weight, blood 
pressure, HbA1c %, fasting glucose, LDL-C, HLD-C, 
cholesterol and triglyceride levels (after overnight, 8 h 
minimum fast), any history of anti-hyperglycaemic or 
anti-hypertensive medication, and any history of car-
diovascular and/or systemic disease.
Characterisation of and inclusion/exclusion criteria 
for participant groups
Obesity was characterised as a BMI ≥30 kg/m2. Patients 
with a history of anti-hyperglycaemic medication were 
permitted within the obese group, due to the increas-
ingly common use of biguanides in pre-diabetic/obese 
patients. T2D was characterised as having three or 
more elevated fasting glucose levels within a 12-month 
period, of  ≥7  mmol/l, with or without a history of 
anti-hyperglycaemic medication. Hypertension was 
characterised as having both elevated diastolic and sys-
tolic blood pressure of ≥140/90  mmHg, with or with-
out a history of anti-hypertensive medication. Those 
patients with controlled hypertension (i.e. history of 
hypertension or use of anti-hypertensive medication, 
with a blood pressure <140/90) were excluded from the 
study. Additional exclusion criteria for patients of all 
groups included history of cardiac disease or systemic 
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disease, age  <18  years, or the collection of accompa-
nying clinical and metabolic medical records within a 
time period >6 months before or after TTE procedure. 
For a more detailed description of the study design see 
Additional file 1.
Blood pressure measurements
Blood pressure (BP) was recorded as per the American 
Heart Association guidelines, with the use of OMRON 
Intelli sense HEM-907 or HBF-1300 and cuff bladder at 
least 80% of the patient’s arm circumference. In the inci-
dence of an elevated BP reading (≥140/90  mmHg), the 
measurement was repeated up to three times. With the 
lowest BP measurement recorded. Pulse pressure mmHg 
was calculated by subtracting diastolic BP from systolic 
BP (systolic BP mmHg–diastolic BP mmHg).
Metabolically healthy vs metabolically non‑healthy 
patients
To separate normotensive obese patients based on 
metabolic health. We adhered to Karelis criteria. 
With metabolically healthy patients determined as; 
fasting glucose  ≤5.5  mmol/l, HDL-C  ≥1.4  mmol/l, 
LDL-C  ≤2.6  mmol/l, cholesterol  ≤5.5  mmol/l and tri-
glycerides  ≤1.8  mmol/l. Patients were categorised as 
being metabolically unhealthy if they exhibited >1 more 
parameter outside these normal ranges.
Transthoracic echocardiography
Sonographers were qualified with a Diploma of Medial 
Ultrasonography or equivalent. Both the sonographers 
that performed the echocardiography and cardiolo-
gists that analysed the results were blinded to the study 
groups, due to the retrospective nature of the study. 
All echocardiograms were performed using the Phil-
lips Ie33 with a S5-1 transducer. A combination of two 
dimensional, M-mode, pulsed wave and continuous 
wave Doppler and tissue Doppler were used. Left ven-
tricular diameter and wall thicknesses were measured in 
the parasternal long axis view using two-dimensional or 
M-mode measurements [left ventricular internal dias-
tolic dimension (LVIDd), left ventricular internal systolic 
dimension (LVISd), interventricular septum dimen-
sion (IVSd), left ventricular posterior wall dimension 
(LVPWd)]. Of note, while M-mode was used to measure 
the LV wall thickness whenever possible, in cases where 
the M-mode was not able to be properly aligned (orthog-
onal) two dimensional echocardiography was used. 
Mitral inflow velocities (E’ velocity, Peak E-wave, Peak 
A-Wave) and deceleration times (DT) were measured 
using pulsed wave Doppler in the apical 4 chamber view. 
Echocardiographic data was analysed using proprietary 
software.
Characterisation of diastolic dysfunction
Diastolic dysfunction (DD) was characterised 
according to the American Society of Echocardiog-
raphy (ASE) guidelines [11]. Patients were graded 
with either normal diastolic function (E′ ≥ 10 cm/s) 
or DD, characterised as Grade 1 (impaired relaxa-
tion) E′  <  10  cm/s, E/A  <  0.8, E/E′  ≤  8; Grade 2 
(pseudonormal) E′  <  10  cm/s, E/A 0.8–1.5, E/E′ 
9–14; or Grade 3 (restrictive) E′ < 10 cm/s, E/A ≥ 2, 
E/E′ > 14.
Left ventricular geometry
LV mass was estimated according to ASE guidelines 
[12], in which LV mass (grams)  =  (0.8·[1.04·(LVED
d  +  IVSd  +  LVPWd)3  −  (LVEDd)3])  +  0.6). LV mass 
was then indexed to body surface area (BSA, g/m2) 
and to height (g/m2.7). RWT was calculated using the 
formula, RWT  =  ((IVSd  +  LVPWd)/LVEDd) and via 
((2·LVPWd)/LVEDd). LV geometry was character-
ised using the following criteria; Normal LV geometry, 
RWT  ≤  42, LVMI (g/m2.7)  ≤51; eccentric hypertro-
phy (EH), RWT  ≤  42, LVMI (g/m2.7)  >51; concentric 
remodelling (CR), RWT  >  42, LVMI (g/m2.7) ≤51 and 
concentric hypertrophy (CH), RWT  >  42, LVMI (g/
m2.7) >51.
Statistical analysis
Continuous variables were represented as means   ±1 
standard deviation (SD), unless otherwise stated. 
Means of continuous variables were analyzed via 
ANOVA assessed with Bonferroni, and associations 
were determined by performing linear regression anal-
ysis, assessed with Pearson’s correlation coefficient. 
Categorical variables were expressed as percentages 
or prevalence and analyzed via Chi square tests, using 
fisher’s exact test. To determine independent predictors 
of categorical variables, multivariable logistic regres-
sion analysis was performed with variables adjusted for 
as detailed. Of note, aortic stenosis was not adjusted 
for as the presence of aortic stenosis (characterised by 
an ascending aorta of  <3.7  cm) did not associate with 
diastolic dysfunction or LV geometric patterns in the 
normotensive patients. p < 0.05 was considered signifi-
cant. All statistical analysis were performed using SPSS 
version 23.
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Results
Basic clinical data
Basic clinical data are presented in Table  1 and Addi-
tional file  1: Table  S1. Of note, normotensive and 
hypertensive patients within the same group were of 
similar age and gender percentage (Table  1). Between 
groups, age was lower in both T2D and Obese/T2D 
groups compared to obese groups (p < 0.001), age was 
however adjusted for in future analysis as detailed.
The co‑existence of obesity and T2D in Normotensive 
patients had additive effects on the prevalence of LVH
The presence of LVH was determined by assessing the 
clinical hypertrophy indices LVPWd and LV mass, which 
were derived from M-Mode measurements (Table  2). 
Additional M-Mode measures are shown in Additional 
file 1: Table S1.
We first confirmed that our patient population 
exhibited normal associations between age and BMI 
Table 1 Basic clinical data
*** p < 0.001 vs same group, different condition, ǂ p < 0.05, ǂǂ p < 0.01, ǂǂǂ p < 0.001 vs obese group, same condition, ××× p < 0.001 vs T2D group, same condition
Group Obese T2D Obese/T2D
Condition Norm. Hyper. Norm. Hyper. Norm. Hyper.
Basic clinical data
 n 58 71 41 74 42 67
 Age (years) 48 ± 2.0 54 ± 1.6 68 ± 1.9ǂǂǂ 68 ± 1.0ǂǂǂ 60 ± 1.9ǂǂǂ 65 ± 1.2ǂǂǂ
 Female  % 59 52 40 43 53 48
 BMI (kg/m2) 34 ± 0.77 37 ± .74 26 ± .40ǂǂǂ 26 ± 0.47ǂǂǂ 36 ± .71××× 36 ± 0.74×××
 Height (cm) 166 ± 1.4 167 ± 1.1 171 ± 1.7 170 ± 1.2 166 ± 1.9 170 ± 1.4
 Heart rate (bpm) 74 ± 1.7 73 ± 1.7 71 ± 2.4 71 ± 2.0 76 ± 2.6 72 ± 1.8
 Systolic BP (mmHg) 127 ± 1.6 159 ± 3.0*** 128 ± 1.6 164 ± 2.0*** 128 ± 1.6 161 ± 2.0***
 Diastolic BP (mmHg) 78 ± 1.1 93 ± .77*** 75 ± 1.2 95 ± .52*** 76 ± 1.5 94 ± 1.5***
 PP (mmHg) 49 ± 1.4 66 ± 2.8*** 52 ± 1.7 69 ± 1.9*** 53 ± 2.5 68 ± 2.2***
 Glucose (mmol/l) 5.2 ± .10 5.2 ± 0.14 8.4 ± 0.49ǂǂǂ 8.5 ± 0.51ǂǂǂ 11 ± 0.72ǂǂǂ 9.1 ± 0.43ǂǂǂ
 Cholesterol (mmol/l) 5.1 ± .24 4.7 ± 0.24 4.1 ± 0.3 4.0 ± 0.16 4.1 ± .22 3.9 ± 0.11
 HDL-C (mmol/l) 1.3 ± .07 1.5 ± 0.13 1.2 ± 0.09 1.2 ± .04 1.2 ± 0.12 1.2 ± 0.05
 LDL-C (mmol/l) 3.1 ± .23 2.6 ± 0.28 2.2 ± 0.21ǂ 1.9 ± 0.11ǂ 1.9 ± 0.16ǂ 1.8 ± 0.10ǂ
 Triglycerides (mmol/l) 1.9 ± 1.3 1.6 ± 0.13 2.0 ± 0.34 1.9 ± 0.16 2.4 ± 0.33 2.4 ± 0.20
History anti-hyperglycaemic and anti-hypertensive medication (%)
 Biguanides 8.62 1.41 26.83ǂǂ 47.30ǂǂ 47.30ǂǂǂ 50.72ǂǂ
 DPP-4 inhibitors 0 0 4.88ǂǂ 6.76ǂǂ 0% 7.46ǂǂ
 Sulphonylureas 0 0 17.07ǂǂ 41.89ǂǂ 33.33ǂǂ 41.79ǂǂ
 Insulin 0 0 24.39ǂǂ 16.22ǂǂ 40.48ǂǂ 25.37ǂǂ
 ACE inhibitors 0 16.90*** 0 33.78*** 0 46.27***
 Ang II antagonists 0 15.14*** 0 20.27*** 0 19.40***
 Beta-blockers 0 18.31*** 0 49.32*** 0 58.21***
 Ca2+ channel blockers 0 11.27*** 0 14.86*** 0 11.94***
Table 2 Echocardiography measurements of left ventricular structure
** p < 0.01, *** p < 0.001, vs same group, different condition; ǂ p < 0.05, ǂǂ p < 0.01, ǂǂǂ p < 0.001, vs obese group, same condition; ××× p < 0.001 vs T2D group, same 
condition
Group Obese T2D Obese/T2D
Condition Norm. Hyper. Norm. Hyper. Norm. Hyper.
M-mode measurements
 IVSd (cm) 1.0 ± 0.03 1.1 ± 0.02** 1.1 ± 0.03 1.1 ± 0.02 1.1 ± 0.03 1.3 ± 0.02ǂǂǂ,×××
 LVIDd (cm) 4.9 ± 0.08 4.8 ± 0.08 4.7 ± 0.11 4.6 ± 0.08 4.6 ± 0.10 4.8 ± 0.05
 LVPWd (cm) 0.9 ± 02 1.1 ± 0.03 1.0 ± 0.03ǂ 1.1 ± 0.03 1.1 ± 0.03ǂǂǂ 1.2 ± 0.02***,ǂǂǂ,×××
 LV mass (g) 159 ± 5.7 191 ± 8.2** 172 ± 8.0 187 ± 5.1 191 ± 8.2 233 ± 6.2***, ǂǂǂ,×××
 LV mass/BSA 76 ± 2.4 88 ± 3.5 90 ± 3.9 103 ± 4.3 90 ± 4.3 106 ± 4.0ǂǂ
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with indices of LVH (Additional file  1: Table S2). Age 
independently correlated with LVPWd (r2  =  0.35, 
p < 0.001), LV mass (r2 = 0.24, p < 0.01), LV mass/BSA 
(g/m2) (r2 =  0.34, p  <  0.001), LV mass/height (g/m2.7) 
(r2  =  0.26, p  <  0.01) and RWT (r2  =  0.38, p  <  0.001) 
in both normotensive and hypertensive subjects. BMI 
independently correlated with LVPWd (r2  =  0.15, 
p < 0.05), LV mass (r2 =  0.16, p < 0.05) and LV mass/
height (g/m2.7; r2 = 0.39, p < 0.001). The same was true 
for hypertensive patients with the addition of a correla-
tion between BMI and LV mass/BSA (g/m2; r2 = −0.25, 
p = 001; Additional file 1: Table S2).
LVPWd was increased in H.Obese and N.Obese/
T2D groups vs N.Obese (1.1 ± 0.03 and 1.1 ± 0.03, vs 
0.9  ±  02, p  <  0.05 and p  <  0.001 respectively) and in 
H.Obese/T2D patients vs all other groups (1.2 ±  0.02, 
p  <  0.001, Table  2). The prevalence of patients within 
each group exhibiting LVPWd above recommended 
ASE guidelines (0.9  cm females, 1.0  cm males) were 
increase between N.Obese vs H.Obese (35.71 vs 64.71%, 
p < 0.05), N.T2D vs H.T2D (39.39 vs 63.89%, p < 0.05), 
N.Obese/T2D vs H.Obese/T2D (64.10 vs 92.54%, 
p  <  0.05) and in both normotensive and hypertensive 
Obese/T2D groups in comparison to Obese and T2D 
groups alone (p < 0.05). This shows that in the absence 
of hypertension, LVPWd measures that are indicative 
of LVH are present in obese and T2D patients (albeit 
at a lower prevalence than in hypertensive patients), 
and that the co-existence of these stresses had an addi-
tive effect on the prevalence of LVPWd above ASE 
guidelines.
Estimated LV mass (grams) was increased between 
N.Obese vs H.Obese (159 ± 5.7 vs 191 ± 8.2, p < 0.01), 
N.Obese/T2D vs H.Obese/T2D (191 ± 8.2 vs 233 ± 6.2, 
p  <  0.001) and in both H.Obese and H.T2D groups vs 
H.Obese/T2D (191  ±  8.2 and 187  ±  5.1 vs 233  ±  6.2, 
both p < 0.001). When indexed to BSA (g/m2), LV mass 
remained increased between only H.Obese vs H.Obese/
T2D (88 ± 3.5 vs 106 ± 4.0, p < 0.01, Table 2). However, 
as indexation of LV mass to BSA in obese patients has 
been suggested to be inaccurate [13], we also indexed 
to height^2.7. Using this method, LV mass/height (g/
m2.7) was increased in H.Obese vs N.Obese (47 ± 1.8 vs 
40 ± 1.5, p < 0.01), N.Obese/T2D vs N.Obese (48 ± 2.4 
vs 40 ± 1.5, p < 0.05) and between H.Obese/T2D vs both 
H.Obese and H.T2D (55 ± 1.8 vs 47 ± 1.8 and 43 ± 1.4, 
p < 0.01 and p < 0.001 respectively) (Fig. 1a). Alarmingly, 
LV mass/height was comparable between normotensive 
Fig. 1 a LV mass/height (g/m2.7), b RWT, Error bars represented as mean ± SD. c Percentage of subjects with normal LV geometry, eccentric 
hypertrophy, concentric remodelling or concentric hypertrophy. **p < 0.01, vs same group, different condition; ǂǂp < 0.01, vs obese group, same 
condition; ××p < 0.01, vs T2D group, same condition
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vs hypertensive T2D and Obese/T2D groups (p = 1.0 and 
p = 0.178, respectively, by ANOVA). When considering 
normotensive vs hypertensive Obese/T2D groups inde-
pendently via a student’s t test, a significant difference in 
LV mass/height was observed (p = 0.023, Fig. 1a).
No difference in the prevalence of concentric 
remodelling and concentric hypertrophy was observed 
between normotensive and hypertensive obese/T2D 
patients
To determine whether the observed increases in LVPWd 
and LV mass were associated with alterations in LV 
geometry, RWT was calculated and used with LV mass/
height to identify normal LV geometry, EH, CR or CH 
[12]. Hypertension increased RWT in obese patients 
(p  <  0.01), while the coexistence of obesity and T2D 
increased RWT compared with obesity alone in both nor-
motensive and hypertensive patients (p  <  0.01, Fig.  1b). 
Calculated LV geometry patterns are shown in Fig. 1c and 
Additional file  1: Figure S1. The percentage of patients 
with normal LV geometry decreased between N.Obese 
vs H.Obese (71 vs 28%, p < 0.001), N.T2D vs H.T2D (52 
vs 29%, p < 0.05), N.Obese/T2D vs H.Obese/T2D (20 vs 
4%, p < 0.05), N.Obese vs N.Obese/T2D (p < 0.001) and 
H.Obese vs H.Obese/T2D (p  <  0.01). The percentage of 
patients with EH increased between N.Obese vs H.Obese 
(6.5 vs 19%, p  <  0.05) and decreased between H.Obese 
vs both H.T2D and H.Obese/T2D (19 vs 4.8% and 4% 
respectively, p  <  0.05). The percentage of patients with 
CR increased between N.Obese vs N.T2D (15 vs 44%, 
p < 0.01). The percentage of patients with CH increased 
between N.Obese vs H.Obese (6 vs 24%, p < 0.01), N.T2D 
vs H.T2D (4 vs 27%, p < 0.01), both N.Obese and N.T2D 
vs N.Obese/T2D (6 and 4% vs 37%, p < 0.001) and both 
H.Obese and H.T2D vs H.Obese/T2D (24 and 27% vs 
55%, p < 0.001). As with LV mass/height, the prevalence 
of CR and CH were comparable between normoten-
sive vs hypertensive Obese/T2D groups (p =  0.629 and 
p = 0.164 respectively). This suggests that, in the absence 
of hypertension, obesity and T2D have an additive effect 
on the development of CH.
Assessment of unadjusted LVPWd alone underestimates LV 
remodelling in normotensive obese and T2D patients
Due to discrepancies in past studies that have assessed 
LVH in normotensive patients with metabolic syn-
drome [14], we determined whether different out-
comes in assessment of LVH would be obtained using 
unadjusted LVPWd, which is commonly used in clini-
cal practice, vs RWT. Interestingly, in those patients 
across all groups characterised with CR, 44% of nor-
motensive patients and 25% hypertensive patients 
(p < 0.05) exhibited LVPWd within normal ASE ranges. 
This analysis was determined using the preferred for-
mula ((IVSd +  LVPWd)/LVID) to derive RWT, as this 
formula assumes asymmetric LV remodelling by taking 
into account both septal and posterior aspects of the LV 
chamber. When using an alternative formula that does 
not include IVSd ((2 × LVPWd)/LVIDd) similar results 
were obtained (data not shown). These findings are fur-
ther supported by the observed differences in LVPWd 
between LV geometric patterns, with patients charac-
terised with EH and CR exhibiting comparable LVPWd 
(1.07 ± 0.01 vs 1.07 ± 0.01), greater than that detected 
in patients with normal LV geometry (0.83  ±  0.01, 
p < 0.001) and lower than that detected in patients with 
CH (1.25 ±  0.02, p  <  0.001, Fig.  2a). As expected due 
to LV geometric characterisation criteria, RWT was 
comparable between patients with normal LV geom-
etry and EH (0.35 ± 0.01 vs 0.39 ± 0.01), increased in 
those exhibiting CR (0.49 ±  0.01, p < 0.001 vs normal 
and EH) and interestingly was further increased in 
those with CH (0.53 ±  0.02, p  <  0.001 vs normal and 
EH, p < 0.05 vs CR, Fig. 2b). These results suggest that 
in obese and/or T2D patients, assessment of unad-
justed LVPWd alone may underestimate the presence of 
LV remodelling and as such, the additional use of RWT 
may provide a more sensitive measure in these patients.
Fig. 2 Normotensive and hypertensive patients grouped based on characterisation of normal LV geometry, eccentric hypertrophy, concentric 
remodelling and concentric hypertrophy. a LVPWd (cm), b RWT. Data represented as mean ± SEM. ǂǂǂp < 0.001 vs normal geometry, ×××p < 0.001 
vs eccentric hypertrophy, +p < 0.05 vs concentric remodelling
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LV geometric patterns associate with differing grades 
of diastolic dysfunction
To assess the prognostic value of characterising LV 
remodelling in normotensive obese and/or T2D patients, 
multivariable logistic regression analysis was used to 
determine whether LV geometric patterns predicted 
diastolic dysfunction.
Again we first confirmed that our patient population 
exhibited normal associations, in this case between age 
and indices of diastolic function (Additional file 1: Table 
S2). In normotensive patients, age correlated with E/A 
ratio (r = −0.25, p < 0.001), E/E′ (r = 0.23, p < 0.01), DT 
(r = 0.11, p < 0.05) and LAVi (r = 0.28, p < 0.001). The 
same was true for hypertensive patients, with the excep-
tion of LAVi. Associations between BMI and indices of 
diastolic function were also assessed, as previous studies 
have yielded conflicting results in this area [15, 16]. How-
ever, no associations between BMI with indices of dias-
tolic function were observed (Additional file 1: Table S2).
CR was a predictor of both grade 1 DD (odds ratio 
(OR) 3.487, p  =  0.038) and grade 3 DD (OR 2.157, 
p =  0.029) when including sex and BMI as covariates. 
With the addition of age as a covariate, the associa-
tion with grade 1 DD remained (OR 3.474, p = 0.045), 
and was lost with grade 3 DD (OR 1.9, p = 0.071). CH 
proved to be a stronger predictor of grade 3 DD (OR 
3.7, p  <  0.001) with the inclusion of sex and BMI as 
covariates. This association was only slightly attenu-
ated with the addition of age as a covariate (OR 3.2, 
p  <  0.005). Supporting these findings, RWT and LV 
mass/height were identified as predictors of grade 3 DD 
(OR 30.28, p  <  0.001 and OR 1.051, p  <  0.001 respec-
tively) when including sex and BMI as covariates. 
With the addition of age as covariate, the association 
between LV mass/height with grade 3 DD was lost (OR 
1.011, p  =  0.337) and was moderately attenuated in 
relation to RWT (OR 19.245, p = 0.012; Table 3). These 
data suggest, that the presence of CR is a predictor of 
grade 1 DD and CH and RWT are predictors of grade 
3 DD, independent of sex, age and BMI in obese and/or 
T2D patients.
The co‑existence of obesity and t2D in normotensive 
patients had an additive effect on the prevalence of grade 
3 diastolic dysfunction
The prevalence of DD in normotensive vs hypertensive 
obese and/or T2D groups irrespective of LV geometric 
type was determined (Fig.  3a–d). Accounting for sex 
and age, normal diastolic function decreased between 
N.Obese vs H.Obese (50 vs 32.4%, p < 0.05) and N.T2D 
vs H.T2D (48.8 vs 24.3%, p < 0.05) groups, grade 1 DD 
increased between N.Obese vs H.Obese (5 vs 17%, 
p  <  0.05) and grade 3 DD increased between N.Obese 
vs H.Obese (13.8 vs 39.2%, p < 0.05), N.T2D vs H.T2D 
(19.5 vs 47.8%, p < 0.05) and N.Obese/T2D vs H.Obese/
T2D (34.1% vs 47.8, p  <  0.05) groups. The prevalence 
of Grade 3 DD in both normotensive and hypertensive 
Obese/T2D patients was greater than that detected in 
obese (p < 0.01) and T2D (p < 0.05) groups alone. These 
results suggest that there is an additive effect on dias-
tolic decline when obesity and T2D co-exist, compared 
to when these stresses present individually.
Systolic function was also assessed, however, all 
groups exhibited indices within the range of normal, as 
per ASE guidelines (Additional file 1: Table S1).
Table 3 Association between left ventricular geometry and structure with diastolic dysfunction
LVH type/indices Grade 1 DD Grade 2 DD Grade 3 DD
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Covariates: LVH type/indices, sex and BMI
 EH 3.1 (0.2–55.7) N/S 2.5 (0.7–8.6) N/S 0.6 (0.2–2.1) N/S
 CR 3.5 (0.1–11.3) 0.038 1.1 (0.5–2.1) N/S 2.2 (1.1–4.3) 0.029
 CH 0.5 (0.1–3.0) N/S 0.7 (0.3–1.4) N/S 3.7 (1.7–8.0) 0.000
 RWT 11.1 (0.2–562) N/S 0.2 (0.02–2.6) N/S 30.1 (3.2–286) 0.000
 LV mass/height 1.1 (1.0–1.1) N/S 1.0 (0.9–1.0) N/S 1.1 (1.0–1.1) 0.000
Covariates: LVH type/indices, sex, BMI and age
 EH 2.4 (0.1–46.1) N/S 2.8 (0.8–10.2) N/S 0.8 (0.2–3.2) N/S
 CR 3.5 (1.1–11.7) 0.045 1.2 (0.6–2.4) N/S 1.9 (0.9–3.9) 0.071
 CH 0.7 (0.–4.8) N/S 0.8 (0.4–1.7) N/S 3.2 (1.4–7.2) 0.003
 RWT 1.0 (0.9–1.0) N/S 1.0 (0.9–1.0) N/S 19.2 (1.9–193) 0.012
 LV mass/height 1.1 (1.0–1.1) N/S 1.0 (0.9–1.1) N/S 1.0 (1.0–1.0) 0.337
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Pulse pressure is an independent predictor of increased 
RWT in normotensive patients
In order to determine which normotensive obese and 
T2D patients were at greatest risk of developing LVH, 
linear regression analysis was used to determine whether 
routinely measured metabolic parameters (Table 1) asso-
ciated with RWT. RWT was chosen as the independent 
variable to detect risk of LVH, as RWT provided the most 
sensitive measure to detect LVH in our normotensive 
patients. In addition, concentric remodelling and con-
centric hypertrophy were the most prevalent types of 
LV geometry detected, for which both have the common 
requirement for increased RWT.
Pulse pressure (Fig. 3e) and fasting glucose (Additional 
file 1: Figure S3A) were associated with RWT (r2 = 0.28, 
p  <  0.001 and r2  =  0.33, p  <  0.001, respectively). Spe-
cifically, pulse pressure  ≥54  mmHg and fasting glu-
cose  ≥7.7  mmol/l were associated with a RWT  >  42, 
a value characteristic of concentric remodelling and 
also concentric hypertrophy when accompanied by an 
increase in LV mass. When accounting for sex, age and 
BMI, the correlations between pulse pressure (r2 = 0.33, 
p  <  0.001), fasting glucose (r2  =  0.35, p  <  0.001) and 
RWT were slightly strengthened. This suggests that these 
parameters can be used to predict risk in normotensive 
obese and/or T2D patients, independent of age and BMI. 
The same associations were not detected in hypertensive 
obese and/or T2D patients (Additional file 1: Figure S3B, 
C). Presumably due to the stronger influences of hyper-
tension on cardiac structure in comparison to obesity 
and T2D.
Normotensive metabolically non‑healthy obese patients 
exhibited increased prevalence of concentric remodelling 
and diastolic dysfunction
As BMI did not associate with RWT or indices of DD in 
our patients (Additional file 1: Tables S2, S3), we aimed 
to determine what factors in normotensive obese patients 
were associated with the observed alterations in LV 
geometry and DD (Figs. 1c, 3b–d). To do this, N.Obese 
patients were stratified into metabolically healthy and 
metabolically non-healthy N.Obese groups (see “Meth-
ods” section). In doing so, we determined that metaboli-
cally healthy N.Obese patients have a relatively low risk 
of concentric remodelling and concentric hypertrophy 
compared with metabolically non-healthy N.Obese, 
exhibiting normal LV geometry at a prevalence of 84.8 
vs 35% (p  <  0.001), concentric remodelling at 5 vs 47% 
(p  <  0.001) and concentric hypertrophy at 5 vs 12% 
(p  <  0.05, Fig.  4a). The prevalence of eccentric remod-
elling remained low in both metabolically healthy and 
non-healthy N.Obese patients (5.2 vs 6%, Fig.  4a). In 
Fig. 3 Percentage of normotensive and hypertensive obese, T2D and obese/T2D groups with a normal diastolic function, b grade 1 DD, c grade 
2 DD and d grade 3 DD. e Linear regression analysis between RWT and Pulse Pressure (mmHg) in normotensive obese and/or T2D patients, 
***p < 0.001 via linear regression analysis. Accounting for sex and age; *p < 0.05 vs same group, different condition, ǂp < 0.05, ǂǂp < 0.01, ǂǂǂp < 0.001 
vs obese group, same condition, ×××p < 0.001 vs T2D group, same condition
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addition, the prevalence of concentric remodelling and 
concentric hypertrophy in normotensive metabolically 
non-health obese patients was comparable to H.Obese 
patients (47 and 12% vs 47 and 25%, p = 1.0 and p = 0.13 
respectively), suggesting that in obese patients, metabolic 
abnormalities have effects similar to hypertension on LV 
remodelling. The prevalence of normal diastolic func-
tion declined between metabolically healthy N.Obese vs 
metabolically non-healthy N.Obese (61 vs 42%, p < 0.05, 
Fig. 4b), while grade 3 DD increased (5.5 vs 20%, p < 0.05, 
Fig. 4e). There were no differences in grade 1 and 2 DD 
between groups (Fig. 4c, d).
Discussion
Despite professional knowledge of the risks associated 
with obesity and T2D in the development of cardiovas-
cular disease, monitoring blood pressure remains the 
first line method when assessing risk in normotensive 
obese and/or T2D patients. While this practice allows 
for the early detection of hypertension, it may not be suf-
ficient to allow for the early detection of LVH and DD. 
Indeed, results from this current study suggest that in 
the absence of hypertension, LVH and DD may be pre-
sent and detectable via TTE in normotensive obese and/
or T2D patients. The major findings from this study are 
that; (1) Significant alterations in LV remodelling indica-
tive of LVH were detected in normotensive metabolically 
non-healthy obese, T2D and obese/T2D patients. (2) 
Assessment of LVPWd via recommended ASE guidelines 
underestimated the presence of LV remodelling. (3) Con-
centric remodelling was a predictor of grade 1 DD and 
concentric hypertrophy and RWT predictors of grade 3 
DD, independent of sex, age and BMI. (4) Normotensive 
patients with an increased risk of a RWT > 42 with those 
exhibiting pulse pressure ≥54 mmHg.
Considering obese patients first, metabolically healthy 
N.Obese patients exhibited a relatively low prevalence 
of LV remodelling, with  >80% of these patients exhibit-
ing normal LV geometry. It was only in those N.Obese 
patients characterised with “poor” metabolic health that 
significant alterations in LV geometry were detected. 
This was particularly true for concentric remodelling 
(47%), which was 9.4 times higher than that in meta-
bolically healthy N.Obese patients and 1.6 times higher 
than that in H.Obese patients. This suggests that obe-
sity per se, as defined by a BMI  ≥  30 (kg/m2), does 
not promote the development of concentric remodel-
ling, but rather it is the metabolic health status of the 
patient with a BMI  ≥  30 (kg/m2) that has the greatest 
influence on increases in RWT. Supporting this claim, 
our study showed that BMI had no association with 
RWT or diagnosis of concentric remodelling. There-
fore, these results suggest additional risk assessment 
should be performed in normotensive obese patients 
with more than one of the following metabolic param-
eters; fasting glucose >5.5 mmol/l, HDL-C <1.4 mmol/l, 
Fig. 4 Percentage of metabolically healthy (MH) and metabolically non-healthy (MNH) normotensive with a normal LV geometry, eccentric hyper-
trophy, concentric remodelling and concentric hypertrophy, b normal diastolic function, c grade 1 DD, d grade 2 DD, and e grade 3 DD. Accounting 
for sex and age; *p < 0.05y vs MH
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LDL-C  >2.6  mmol/l, cholesterol  >5.5  mmol/l and 
triglycerides >1.8 mmol.
H.Obese patients on the other hand exhibited not only 
concentric remodelling (28%) but also concentric hyper-
trophy (25%), at a prevalence 4.8 and 2 times higher than 
that in metabolically healthy and non-healthy N.Obese 
patients respectively. This is consistent with previous 
studies in which autopsy results identified hypertensive 
obese patients to exhibit both concentric remodelling 
and concentric hypertrophy and for normotensive obese 
patients to present with mainly concentric remodel-
ling [17]. N.T2D patients exhibited similar alterations in 
LV geometry as metabolically non-healthy obese, show-
ing a comparable prevalence of concentric remodelling 
(44%) and a low prevalence of concentric hypertrophy 
(4%), 6.75 times lower than that in H.T2D patients. Inter-
estingly, it was only in those N.Obese/T2D patients in 
which the predominant LV geometric patterns detected 
included both concentric remodelling (30%) and concen-
tric hypertrophy (36%), which was comparable to that 
in H.Obese patients. These results suggests that the co-
existence of obesity and T2D in normotensive patients 
had an effect on the development of CH which was simi-
lar to the negative influence hypertension had when cou-
pled with obesity or T2D alone.
To our knowledge, this is the first study reporting 
that the use of unadjusted LVPWd vs RWT underesti-
mated the presence of LV remodelling in obese and T2D 
patients. This had particular relevance in normotensive 
patients, with 45% of those characterised with concentric 
remodelling exhibiting LVPWd within the ranges of nor-
mal ASE guidelines. This result was unchanged regard-
less of how RWT was derived. However, consideration of 
septal wall thickening was preferred due to the presence 
of asymmetric LV remodelling in some patients, with 
IVSd showing similar patterns of enlargement as LVPWd 
within our groups (Additional file 1: Table S1). Of note, 
this increase in septal thickening was accompanied by 
aortic stenosis, with a thinning of the proximal ascend-
ing aorta correlating with increased IVSd (r  =  0.24, 
p = 0.001, data not shown), a correlation that has previ-
ously been identified in subjects with asymmetric remod-
elling [18]. These data suggest that in normotensive obese 
and/or T2D patients assessment of unadjusted LVPWd 
alone may underestimate the presence of LV remodelling 
(both symmetric and asymmetric) and, as such, the addi-
tional use of RWT may provide a more sensitive measure 
in these patients.
The implications of underestimating LV remodel-
ling are evident in this study with the use of multivari-
able logistic regression analysis identifying an association 
between concentric remodelling with diagnosis of grade 
1 DD and concentric hypertrophy and RWT with grade 3 
DD (independent of sex, age and BMI). This suggests that 
reliance on unadjusted LVPWd in normotensive obese 
and T2D patients underestimates not only LV remod-
elling, but also associated cardiovascular risk. While 
previous studies have identified associations between 
LV geometry with adverse cardiac function and cardio-
vascular risk [19–24], these studies have predominately 
focused on hypertensive patients or have not had access 
to subject data regarding hypertension. The data from 
this study provides insight into the prognostic value of 
LV geometry, specifically in normotensive obese and 
T2D patients.
While subject numbers in the present study were low, 
the identification that pulse pressure and fasting glucose 
to be associated with RWT may assist health practition-
ers in narrowing down the otherwise large patient pool of 
at risk individuals to which this study relates, with pulse 
pressure  ≥54  mmHg and fasting glucose  ≥7.7  mmol 
predictors of RWT  >  42. RWT was chosen as an inde-
pendent variable to detect risk of LVH due to concen-
tric remodelling and concentric hypertrophy being the 
predominant LV geometric patterns detected for which 
both have the common requirement for increased RWT. 
In addition, RWT provided a more sensitive measure to 
detected LV remodelling in our patients and increases in 
RWT have previously been associated with adverse car-
diovascular events [9, 25, 26]. In healthy subjects normal 
pulse pressure levels have been detected at 40  mmHg. 
The recorded pulse pressure measurements in the cur-
rent study were increased, averaging >50 mmHg in nor-
motensive and  >60  mmHg in hypertensive patients. 
Similar increases in pulse pressure have previously been 
recorded in subjects with metabolic syndrome [27, 28]. 
To our knowledge, this is the first study identifying the 
use of pulse pressure as a predictor of increased RWT 
that can be applied to all normotensive obese, T2D and 
obese/T2D patients. In a dataset from the HyperGEN 
study [29] normotensive subjects with a higher pulse 
pressure (>60 mmHg) were associated with an increased 
prevalence of thickening of the LVPWd and increased 
RWT. This pulse pressure quartile however contained a 
lower average BMI (27.06 kg/m2) and percentage of T2D 
subjects (3.97%) compared to current study.
Fasting glucose, has been associated with indices 
of LVH in the past [30]. Furthermore, patients with 
impaired fasting glucose or T2D have previously been 
reported to exhibit a 9 and 11% respectively increase 
in the prevalence in concentric remodelling than that 
in euglycemic patients (of note, 46% of patients were 
hypertensive) [31]. The identification of the association 
with fasting glucose with RWT in the current study was 
strengthened when accounting for age and BMI. When 
comparing the use of fasting glucose vs pulse pressure 
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as a predictor of increased RWT via multivariable step-
wise regression analysis, fasting glucose was a stronger 
predictor of RWT (data not shown). In regards to the 
practicality of using pulse pressure and fasting glu-
cose as markers of increased risk, these parameters are 
already routinely collected in normotensive obese and 
T2D patients, therefore their use will not result in an 
additional burden in either cost or time. However, it 
should be noted that although the presence of elevated 
pulse pressure and fasting glucose were associated with 
LV remodelling, this study is not suggesting that these 
are a requirement and, as such should not provide a 
means to exclude patients at risk.
There are some limitations that need to be consid-
ered when interpreting the findings from this study. In 
regards to diastolic function, the reader is reminded 
that these measurements were obtained from an assess-
ment at one time point and that diastolic function may 
vary between examinations. Furthermore, the size of 
the research groups were limited, more hypertensive vs 
normotensive patients were included in the study and 
analysis was restricted to patients of one ethnic group. 
The strengths of the study included providing clearly 
separated normotensive and hypertensive obese, T2D 
and obese/T2D patients. Allowing us to tease out the 
influences of these conditions individually and in com-
bination. Furthermore, despite the restricted patient 
numbers in the study we ensured that our dataset exhib-
ited the normal associations between age with diastolic 
decline and LV structure, adding confidence that the 
findings from this study are relevant to the wider popula-
tion. In addition, we have focused our analysis on echo-
cardiography techniques and clinical measurements that 
are already routinely measured in day to day practice, 
increasing the application potential of the study.
Conclusion
In summary, the data from this current study sug-
gest that in the absence of hypertension, metabolically 
non-healthy obese, T2D and obese/T2D patients are 
at risk of LVH and LV remodelling and that this risk is 
increased when accompanied by increased pulse pres-
sure or fasting glucose. The identification of LVPWd vs 
RWT to underestimate LV remodelling in normoten-
sive obese and/or T2D patients suggests that the use of 
RWT may provide a more sensitive measure in future 
studies and in risk assessment in these patient groups.
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